English

Annual General Meeting of BioGaia

Report this content

The Annual General Meeting of BioGaia AB (publ) on 10 May 2016 voted to approve the following resolutions:

  • adoption of the annual report
  • discharge from liability for the Board members and the Managing Director
  • a dividend of SEK 5.00 per share
  • re-election of Board members Jan Annwall, Ewa Björling, David Dangoor, Stefan Elving, Inger Holmström, Anthon Jahreskog, Brit Stakston and Paula Zeilon
  • re-election of David Dangoor as Board Chairman
  • re-election of the registered Accounting firm Deloitte AB
  • Board member compensation in an amount of SEK 300,000 to the Chairman and SEK 150,000 to each of the other Board members not employed by the company
  • auditors’ fee shall be paid according to approved account
  • regarding principles for remuneration and other terms of employment for senior executives in accordance with the Board’s proposal
  • regarding the Nominating Committee in accordance with the Nominating Committee’s proposal

Latest press releases from BioGaia
2016-05-10 BioGaia AB Interim management statement 1 January – 31 March 2016
2016-05-02 Yet another meta-analysis confirms the effectiveness of BioGaia’s probiotic in infantile colic
2016-04-27 BioGaia guarantees rights issue in IBT

For additional information please contact
Axel Sjöblad, Managing Director, BioGaia: +46 8 555 293 00

BioGaia is a healthcare company that develops, markets and sells probiotic products with documented health benefits. The products are primarily based on the lactic acid bacterium Lactobacillus reuteri which has probiotic, health-enhancing effects. The class B share of the Parent Company BioGaia AB is quoted on the Mid Cap list of NASDAQ Stockholm main market. www.biogaia.com

Subscribe

Documents & Links